IVBIY (Innovent Biologics) Price-to-Operating-Cash-Flow : 95.75 (As of Dec. 15, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Innovent Biologics Price-to-Operating-Cash-Flow?

As of today (2024-12-15), Innovent Biologics's share price is $19.15. Innovent Biologics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.20. Hence, Innovent Biologics's Price-to-Operating-Cash-Flow Ratio for today is 95.75.

The historical rank and industry rank for Innovent Biologics's Price-to-Operating-Cash-Flow or its related term are showing as below:

IVBIY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 96.14 Med: 376.92 Max: 491.83
Current: 96.14

During the past 8 years, Innovent Biologics's highest Price-to-Operating-Cash-Flow Ratio was 491.83. The lowest was 96.14. And the median was 376.92.

IVBIY's Price-to-Operating-Cash-Flow is ranked worse than
87.16% of 296 companies
in the Biotechnology industry
Industry Median: 25.685 vs IVBIY: 96.14

Innovent Biologics's Cash Flow from Operations per share for the six months ended in Jun. 2024 was $-0.07. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.20.

During the past 8 years, Innovent Biologics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 20.80% per year. The lowest was -62.90% per year. And the median was 11.35% per year.

Innovent Biologics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Innovent Biologics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Price-to-Operating-Cash-Flow Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

411.06

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial											-	-	-	411.06	-

Competitive Comparison of Innovent Biologics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Innovent Biologics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Price-to-Operating-Cash-Flow falls into.

Innovent Biologics Price-to-Operating-Cash-Flow Calculation

Innovent Biologics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	19.15	/	0.2
	=	95.75

Innovent Biologics's Share Price of today is $19.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.20.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Innovent Biologics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (OTCPK:IVBIY) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

IVBXF:USA 01801:Hong Kong 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.